Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inserting Prevnar 13 Into Adult Treatment Guidelines Could Raise Questions For Practitioners

Executive Summary

Uncertainty about the effect of Pfizer’s vaccine in patients that have already had Merck’s Pneumovax 23 could cause problems.

You may also be interested in...



FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial

Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.

ANDA Approval Records Will End As US FDA Mops Up Backlog

CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.

Commissioner Nominee's Required Divestitures Illustrate US FDA's Broader Recruitment Challenge

Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.

Topics

Related Companies

UsernamePublicRestriction

Register

PS053983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel